A Phase 1 interventional study of MT1011 and Placebo in Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation, sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects. Includes 5 dose cohorts, with 40 subjects planned for enrollment.
Shaanxi Micot Pharmaceutical Technology Co., Ltd. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Interventional: The SAD study involves single administration of MT1011
Drug: MT1011
Placebo: The SAD study involves single administration of Placebo.
Drug: Placebo
MT1011 is a novel synthetic small molecule anticoagulant reversal agent for reversing anticoagulant effects including factor IIa and Xa inhibitors.
This intervention contains no active ingredients
Incidence and severity of AEs (Adverse Events) and SAEs (Serious Adverse Events)and treatment-related adverse events (TEAEs).
The occurrence of all adverse events (AEs), serious adverse events (SAEs)
Time frame: up to Day 14
Cmax of MT1011
Cmax - Maximum plasma concentration
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 5min,15min,0.5,1, 2, 4, 8, 12, 24, 48 hours post-dose.
Tmax of MT1011
Tmax - Time to reach Cmax
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 5min,15min,0.5,1, 2, 4, 8, 12, 24, 48 hours post-dose.
T1/2 of MT1011
t1/2 - Elimination half-life
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 5min,15min,0.5,1, 2, 4, 8, 12, 24, 48 hours post-dose.
AUC0-tau of MT1011
AUC0-tau - Area under the plasma concentration-time curve during one dosing interval
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 5min,15min,0.5,1, 2, 4, 8, 12, 24, 48 hours post-dose.
AUC0-t of MT1011
AUC0-t - Area under the plasma concentration-time curve from time zero to the last measurable concentration
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 5min,15min,0.5,1, 2, 4, 8, 12, 24, 48 hours post-dose.
Whole blood clotting time
Whole blood clotting time
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.
Activated partial thromboplastin time
Activated partial thromboplastin time
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.
Prothrombin time
Prothrombin time
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.
fibrinogen
fibrinogen
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.
International normalized ratios
International normalized ratios
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.
Thrombin time
Thrombin time
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.
Factor Xa activity
Factor Xa activity
Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.
Started Jun 2025 (actual). Primary completion is estimated for Apr 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shaanxi Micot Pharmaceutical Technology Co., Ltd.